Azienda Ospedaliera San Gerardo, Monza, Italy.
Ospedale di Circolo e Fondazione Macchi, Varese, Italy.
Sci Rep. 2023 Jul 28;13(1):12255. doi: 10.1038/s41598-023-39386-x.
Nowadays, treatment of metastatic breast cancer (MBC) has been enriched with novel therapeutical strategies. Metronomic chemotherapy (mCHT) is a continuous and frequent administration of chemotherapy at a lower dose and so whit less toxicity. Thus, this strategy could be attractive for elderly MBC patients. Aim of this analysis is to provide insights into mCHT's activity in a real-life setting of elderly MBC patients. Data of patients ≥ 75 years old included in VICTOR-6 study were analyzed. VICTOR-6 is a multicentre, Italian, retrospective study, which collected data on mCHT in MBC patients treated between 2011 and 2016. A total of 112 patients were included. At the beginning of mCHT, median age was 81 years (75-98) and in 33% of the patients mCHT was the first line choice. Overall Response Rate (ORR) and Disease Control Rate (DCR) were 27.9% and 79.3%, respectively. Median PFS ranged between 7.6 and 9.1 months, OS between 14.1 and 18.5 months. The most relevant toxicity was the hematological one (24.1%); severe toxicity (grade 3-4) ranged from 0.9% for skin toxicity up to 8% for hematologic one. This is a large study about mCHT in elderly MBC patients, providing insights to be further investigated in this subgroup of frail patients.
如今，转移性乳腺癌（MBC）的治疗方法已经丰富了新的治疗策略。节拍化疗（mCHT）是一种以较低剂量连续和频繁给予化疗的方法，因此毒性较小。因此，这种策略对于老年 MBC 患者可能具有吸引力。本分析旨在为 mCHT 在老年 MBC 患者的真实环境中的活性提供深入了解。分析了 VICTOR-6 研究中纳入的≥75 岁患者的数据。VICTOR-6 是一项多中心、意大利、回顾性研究，收集了 2011 年至 2016 年间接受 mCHT 的 MBC 患者的数据。共纳入 112 例患者。在开始 mCHT 时，中位年龄为 81 岁（75-98 岁），33%的患者将 mCHT 作为一线选择。总缓解率（ORR）和疾病控制率（DCR）分别为 27.9%和 79.3%。中位无进展生存期（PFS）在 7.6 至 9.1 个月之间，总生存期（OS）在 14.1 至 18.5 个月之间。最相关的毒性是血液学毒性（24.1%）；严重毒性（3-4 级）从皮肤毒性的 0.9%到血液学毒性的 8%不等。这是一项关于老年 MBC 患者 mCHT 的大型研究，为这一脆弱患者亚组提供了进一步研究的见解。
